List of NuCana patents

Patents where

Current Assignee

Name

NuCana

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10117888 Formulation comprising a gemcitabine-prodrug	Patent 10117888 was granted and assigned to NuCana on November, 2018 by the United States Patent and Trademark Office.	NuCana	NuCana	United States Patent and Trademark Office	10117888	November 6, 2018
‌ US Patent 11400107 Cancer treatments	Patent 11400107 was granted and assigned to NuCana on August, 2022 by the United States Patent and Trademark Office.	NuCana	NuCana	United States Patent and Trademark Office	11400107	August 2, 2022
‌ US Patent 10993957 Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer	Patent 10993957 was granted and assigned to NuCana on May, 2021 by the United States Patent and Trademark Office.	‌ Nucana PLC	NuCana	United States Patent and Trademark Office	10993957	May 4, 2021
‌ US Patent 11414452 Synthesis of phosphate derivatives	Patent 11414452 was granted and assigned to NuCana on August, 2022 by the United States Patent and Trademark Office.	NuCana	NuCana	United States Patent and Trademark Office	11414452	August 16, 2022
‌ US Patent 11559542 Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer	Patent 11559542 was granted and assigned to NuCana on January, 2023 by the United States Patent and Trademark Office.	NuCana	NuCana	United States Patent and Trademark Office	11559542	January 24, 2023
‌ US Patent 11352387 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds		NuCana	NuCana	United States Patent and Trademark Office	11352387	June 7, 2022
‌ US Patent 11414451 Floxuridine synthesis	Patent 11414451 was granted and assigned to NuCana on August, 2022 by the United States Patent and Trademark Office.	NuCana	NuCana	United States Patent and Trademark Office	11414451	August 16, 2022
‌ US Patent 11603382 Diastereoselective synthesis of phosphate derivatives	Patent 11603382 was granted and assigned to NuCana on March, 2023 by the United States Patent and Trademark Office.	NuCana	NuCana	United States Patent and Trademark Office	11603382	March 14, 2023
‌ US Patent 11629164 Gemcitabine prodrugs	Patent 11629164 was granted and assigned to NuCana on April, 2023 by the United States Patent and Trademark Office.	NuCana	NuCana	United States Patent and Trademark Office	11629164	April 18, 2023
‌ US Patent 11560400 Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds		NuCana	NuCana	United States Patent and Trademark Office	11560400	January 24, 2023
‌ US Patent 10906929 Phosphoramidate nucleoside derivatives as anticancer agents	Patent 10906929 was granted and assigned to NuCana on February, 2021 by the United States Patent and Trademark Office.	NuCana	NuCana	United States Patent and Trademark Office	10906929	February 2, 2021
‌ US Patent 11040051 Formulation comprising a gemcitabine-prodrug	Patent 11040051 was granted and assigned to NuCana on June, 2021 by the United States Patent and Trademark Office.	NuCana	NuCana	United States Patent and Trademark Office	11040051	June 22, 2021
‌ US Patent 10570168 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds	Patent 10570168 was granted and assigned to NuCana on February, 2020 by the United States Patent and Trademark Office.	NuCana	NuCana	United States Patent and Trademark Office	10570168	February 25, 2020
‌ US Patent 10786523 Formulation comprising a gemcitabine-prodrug	Patent 10786523 was granted and assigned to NuCana on September, 2020 by the United States Patent and Trademark Office.	NuCana	NuCana	United States Patent and Trademark Office	10786523	September 29, 2020
‌ US Patent 11377467 Crystalline form of gemcitabine	Patent 11377467 was granted and assigned to NuCana on July, 2022 by the United States Patent and Trademark Office.	NuCana	NuCana	United States Patent and Trademark Office	11377467	July 5, 2022
‌ US Patent 11040997 Process for preparing nucleoside prodrugs	Patent 11040997 was granted and assigned to NuCana on June, 2021 by the United States Patent and Trademark Office.	NuCana	NuCana	United States Patent and Trademark Office	11040997	June 22, 2021
‌ US Patent 10662213 Gemcitabine prodrugs	Patent 10662213 was granted and assigned to NuCana on May, 2020 by the United States Patent and Trademark Office.	NuCana	NuCana	United States Patent and Trademark Office	10662213	May 26, 2020
‌ US Patent 10669300 Methods of separating gemcitabine-phosphate diastereoisomers	Patent 10669300 was granted and assigned to NuCana on June, 2020 by the United States Patent and Trademark Office.	NuCana	NuCana	United States Patent and Trademark Office	10669300	June 2, 2020
‌ US Patent 10660912 Combination therapy for cancer	Patent 10660912 was granted and assigned to NuCana on May, 2020 by the United States Patent and Trademark Office.	NuCana	NuCana	United States Patent and Trademark Office	10660912	May 26, 2020
‌ US Patent 11707477 Formulation comprising a gemcitabine-prodrug		NuCana	NuCana	United States Patent and Trademark Office	11707477	July 25, 2023
‌ US Patent 11786544 Formulations of phosphoramidate derivatives of nucleoside drugs	Patent 11786544 was granted and assigned to NuCana on October, 2023 by the United States Patent and Trademark Office.	NuCana	NuCana	United States Patent and Trademark Office	11786544	October 17, 2023

21 results

0 selected

21 results

0 selected